Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salbutamol sulfate, quantity: 6 mg (equivalent: salbutamol, qty 5 mg) - inhalation, conventional - excipient ingredients: sulfuric acid; water for injections; sodium chloride - for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise induced asthma or in other situations known to induce bronchospasm.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salbutamol sulfate, quantity: 3 mg (equivalent: salbutamol, qty 2.5 mg) - inhalation, conventional - excipient ingredients: water for injections; sulfuric acid; sodium chloride - for the relief of bronchospasm in patients with asthma or chronic obstructive pulmonary disease, and for acute prophylaxis against exercise induced asthma or in other situations known to induce bronchospasm.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - salbutamol sulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - salbutamol sulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - salbutamol sulfate -

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - salbutamol sulfate -

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - salbutamol sulfate 120.5ug equivalent to 100 µg dose (10% excess may be added to compensate for manufacturing loss);   - aerosol inhaler, metered dose - 100 mcg/dose - active: salbutamol sulfate 120.5ug equivalent to 100 µg dose (10% excess may be added to compensate for manufacturing loss)   excipient: norflurane - salbutamol is a selective ?2 adrenoceptor agonist indicated for the treatment or prevention of bronchospasm. it provides short acting (four hours) bronchodilation in reversible airways obstruction due to asthma, chronic bronchitis and emphysema. for patients with asthma salbutamol may be used to relieve symptoms when they occur and to prevent them prior to a known trigger. bronchodilators should not be the only or main treatment in patients with persistent asthma. in patients with persistent asthma unresponsive to salbutamol, treatment with inhaled corticosteroids is recommended to achieve and maintain control. failure to respond promptly or fully to such rescue medication signals a need for urgent medical advice and treatment.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - salbutamol sulfate 120ug equivalent to salbutamol 100 µg;   - aerosol inhaler, metered dose - 100 mcg - active: salbutamol sulfate 120ug equivalent to salbutamol 100 µg   excipient: ethanol norflurane oleic acid

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

approved prescription services ltd - salbutamol sulfate - oral tablet - 4mg

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - salbutamol sulfate 120ug equivalent to salbutamol 100 µg;   - aerosol inhaler, metered dose - 100 mcg/dose - active: salbutamol sulfate 120ug equivalent to salbutamol 100 µg   excipient: ethanol norflurane oleic acid - with its fast onset of action, it is particularly suitable for the management and prevention of attack in mild asthma and for the treatment of acute exacerbations in moderate and severe asthma.